Bioline RX Ltd Sponsored ADR (YP2) AI Stock Analysis

Bioline RX Ltd Sponsored ADR

(Frankfurt:YP2)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

GLIX1 Pipeline DifferentiationGLIX1 provides BioLineRx with a differentiated oncology growth opportunity beyond APHEXDA. Preclinical activity in treatment-resistant glioblastoma and synergy in ovarian cancer support broader development potential, while the planned clinical expansion creates several paths for future value creation.

Negative Factors

Deep Losses and Shrinking RevenueThe current revenue base is not sufficient to support operating expenses, leaving BioLineRx deeply loss-making despite a roughly 70% gross margin. Shrinking revenue and sustained operating losses weaken internal funding capacity and make durable profitability dependent on product adoption or pipeline success.

Bioline RX Ltd Sponsored ADR (YP2) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 9.91M
Dividend Yield: ―
Average Volume (3M): 352
Price to Earnings (P/E): -1.0
Beta (1Y): -1.00
Revenue Growth: -92.56%
EPS Growth: 57.18%
Country: Germany
Employees: 22
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Bioline RX Ltd Sponsored ADR Business Overview & Revenue Model

Company Description

BioLineRx Ltd., an Israeli biopharmaceutical firm established in 2003 and based in Hevel Modi'in, focuses its clinical-stage development efforts primarily on oncology. Their leading investigational product, Motixafortide, a peptide, has successfully...

Bioline RX Ltd Sponsored ADR Earnings Call Summary

Earnings Call Date:Aug 30, 2026(Q2-2026)|% Change Since:-27.10%|Next Earnings Date:May 26, 2025

Earnings Call SentimentPositive

The call was broadly positive, driven by strong GLIX1 clinical enrollment and early safety and tolerability, encouraging glioblastoma and ovarian-cancer preclinical results, continued PDAC trial enrollment, APHEXDA royalty generation, and a cash runway extending into the first half of 2027. Offsetting points included a higher quarterly net loss, flat revenue, uncertainty around the evolving PDAC treatment landscape, and the substantial work still required to expand APHEXDA adoption.

Positive Updates

GLIX1 Clinical Trial Progress

BioLineRx initiated the Phase I/IIa GLIX1 trial in March, dosed the first patient in April at NYU Langone Health, and has since enrolled patients at Northwestern University and Moffitt Cancer Center. Recruitment is progressing extremely well and according to plan; dosing has begun in the second of five planned Phase I cohorts, with the third cohort expected to commence dosing in September. The company reported that GLIX1 has shown very good safety and tolerability a little more than four months into the study and continues to anticipate Phase I data in the first half of 2027.

Negative Updates

Quarterly Net Loss Increased

Net loss for the quarter ended June 30, 2026, was $4.3 million compared with $3.9 million in the 2025 quarter, an increase of $0.4 million or approximately 10.3%.

Company Guidance

BioLineRx expects the third of 5 planned GLIX1 Phase I cohorts to commence dosing in September, with the Phase I part expected to recruit up to 30 patients and Phase I data anticipated in the first half of 2027; the Phase IIa expansion is planned to include additional cohorts, including GBM, newly diagnosed and/or recurrent, as well as additional cancers with or without standard of care, for example, PARP inhibitors. The CheMo4METPANC trial’s prespecified interim/futility analysis is planned when 40% of progression-free survival events are observed, expected later this year. Cash and equivalents of $13.1 million are sufficient to fund the operating plan as currently contemplated into the first half of 2027, and the $3.75 million offering is expected to close later today.

Bioline RX Ltd Sponsored ADR Risk Analysis

Bioline RX Ltd Sponsored ADR disclosed 43 risk factors in its most recent earnings report. Bioline RX Ltd Sponsored ADR reported the most risks in the "Tech & Innovation" category.

Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

1 New Risk

1.We are currently operating in a period of economic uncertainty and capital markets disruption, which has been significantly impacted by geopolitical instability due to the ongoing military conflict between Russia and Ukraine.Q4, 2021

Bioline RX Ltd Sponsored ADR Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:YP2 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AEON	48Neutral	$16.19M	-0.07	204.18%	―	―	35.03%
CTXR	43Neutral	$14.36M	-0.25	-67.15%	―	―	57.48%
KALA	43Neutral	$3.20M	-0.00	-222.32%	―	―	78.25%
DARE	42Neutral	$13.76M	-0.89	-748.08%	―	―	―
GTBP	42Neutral	$10.96M	-0.05	-443.08%	―	―	75.09%

* Healthcare Sector Average

Performance Comparison

DE:YP2 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:YP2	Bioline RX Ltd Sponsored ADR	1.56	-1.22	-43.88%
DARE	Daré Bioscience	0.70	-1.11	-61.38%
GTBP	Gt Biopharma, Inc.	5.32	-10.13	-65.56%
KALA	Kala Bio, Inc.	0.17	-37.41	-99.56%
CTXR	Citius Pharma	0.52	-0.84	-61.54%
AEON	Aeon Biopharma, Inc.	0.27	-0.68	-71.16%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Bioline RX Ltd Sponsored ADR AI Stock Analysis